1001 related articles for article (PubMed ID: 17278996)
21. Behavioral and anatomical abnormalities in Mecp2 mutant mice: a model for Rett syndrome.
Stearns NA; Schaevitz LR; Bowling H; Nag N; Berger UV; Berger-Sweeney J
Neuroscience; 2007 May; 146(3):907-21. PubMed ID: 17383101
[TBL] [Abstract][Full Text] [Related]
22. Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome.
Asaka Y; Jugloff DG; Zhang L; Eubanks JH; Fitzsimonds RM
Neurobiol Dis; 2006 Jan; 21(1):217-27. PubMed ID: 16087343
[TBL] [Abstract][Full Text] [Related]
23. Targeted delivery of an Mecp2 transgene to forebrain neurons improves the behavior of female Mecp2-deficient mice.
Jugloff DG; Vandamme K; Logan R; Visanji NP; Brotchie JM; Eubanks JH
Hum Mol Genet; 2008 May; 17(10):1386-96. PubMed ID: 18223199
[TBL] [Abstract][Full Text] [Related]
24. Mechanisms of disease: neurogenetics of MeCP2 deficiency.
Francke U
Nat Clin Pract Neurol; 2006 Apr; 2(4):212-21. PubMed ID: 16932552
[TBL] [Abstract][Full Text] [Related]
25. Neural development of methyl-CpG-binding protein 2 null embryonic stem cells: a system for studying Rett syndrome.
Okabe Y; Kusaga A; Takahashi T; Mitsumasu C; Murai Y; Tanaka E; Higashi H; Matsuishi T; Kosai K
Brain Res; 2010 Nov; 1360():17-27. PubMed ID: 20816763
[TBL] [Abstract][Full Text] [Related]
26. Monoamine deficits in the brain of methyl-CpG binding protein 2 null mice suggest the involvement of the cerebral cortex in early stages of Rett syndrome.
Santos M; Summavielle T; Teixeira-Castro A; Silva-Fernandes A; Duarte-Silva S; Marques F; Martins L; Dierssen M; Oliveira P; Sousa N; Maciel P
Neuroscience; 2010 Oct; 170(2):453-67. PubMed ID: 20633611
[TBL] [Abstract][Full Text] [Related]
27. Evidence for both neuronal cell autonomous and nonautonomous effects of methyl-CpG-binding protein 2 in the cerebral cortex of female mice with Mecp2 mutation.
Belichenko NP; Belichenko PV; Mobley WC
Neurobiol Dis; 2009 Apr; 34(1):71-7. PubMed ID: 19167498
[TBL] [Abstract][Full Text] [Related]
28. Abnormalities of social interactions and home-cage behavior in a mouse model of Rett syndrome.
Moretti P; Bouwknecht JA; Teague R; Paylor R; Zoghbi HY
Hum Mol Genet; 2005 Jan; 14(2):205-20. PubMed ID: 15548546
[TBL] [Abstract][Full Text] [Related]
29. Expression of methyl CpG binding protein 2 (Mecp2) during the postnatal development of the mouse brainstem.
Dura E; Villard L; Roux JC
Brain Res; 2008 Oct; 1236():176-84. PubMed ID: 18761004
[TBL] [Abstract][Full Text] [Related]
30. Rett syndrome: from the gene to the disease.
Matijevic T; Knezevic J; Slavica M; Pavelic J
Eur Neurol; 2009; 61(1):3-10. PubMed ID: 18948693
[TBL] [Abstract][Full Text] [Related]
31. Glatiramer acetate (GA, Copolymer-1) an hypothetical treatment option for Rett syndrome.
Ben-Zeev B; Aharoni R; Nissenkorn A; Arnon R
Med Hypotheses; 2011 Feb; 76(2):190-3. PubMed ID: 20951500
[TBL] [Abstract][Full Text] [Related]
32. MECP2 mutations and clinical correlations in Greek children with Rett syndrome and associated neurodevelopmental disorders.
Psoni S; Sofocleous C; Traeger-Synodinos J; Kitsiou-Tzeli S; Kanavakis E; Fryssira-Kanioura H
Brain Dev; 2012 Jun; 34(6):487-95. PubMed ID: 21982064
[TBL] [Abstract][Full Text] [Related]
33. The transcriptional repressor Mecp2 regulates terminal neuronal differentiation.
Matarazzo V; Cohen D; Palmer AM; Simpson PJ; Khokhar B; Pan SJ; Ronnett GV
Mol Cell Neurosci; 2004 Sep; 27(1):44-58. PubMed ID: 15345242
[TBL] [Abstract][Full Text] [Related]
34. MeCP2 mutation causes distinguishable phases of acute and chronic defects in synaptogenesis and maintenance, respectively.
Palmer A; Qayumi J; Ronnett G
Mol Cell Neurosci; 2008 Apr; 37(4):794-807. PubMed ID: 18295506
[TBL] [Abstract][Full Text] [Related]
35. Clinical profiles of four patients with Rett syndrome carrying a novel exon 1 mutation or genomic rearrangement in the MECP2 gene.
Bartholdi D; Klein A; Weissert M; Koenig N; Baumer A; Boltshauser E; Schinzel A; Berger W; Mátyás G
Clin Genet; 2006 Apr; 69(4):319-26. PubMed ID: 16630165
[TBL] [Abstract][Full Text] [Related]
36. MECP2 is progressively expressed in post-migratory neurons and is involved in neuronal maturation rather than cell fate decisions.
Kishi N; Macklis JD
Mol Cell Neurosci; 2004 Nov; 27(3):306-21. PubMed ID: 15519245
[TBL] [Abstract][Full Text] [Related]
37. MeCP2 and Rett syndrome: reversibility and potential avenues for therapy.
Gadalla KK; Bailey ME; Cobb SR
Biochem J; 2011 Oct; 439(1):1-14. PubMed ID: 21916843
[TBL] [Abstract][Full Text] [Related]
38. Homeostatic regulation of MeCP2 expression by a CREB-induced microRNA.
Klein ME; Lioy DT; Ma L; Impey S; Mandel G; Goodman RH
Nat Neurosci; 2007 Dec; 10(12):1513-4. PubMed ID: 17994015
[TBL] [Abstract][Full Text] [Related]
39. A transcriptional repressor MeCP2 causing Rett syndrome is expressed in embryonic non-neuronal cells and controls their growth.
Nagai K; Miyake K; Kubota T
Brain Res Dev Brain Res; 2005 Jun; 157(1):103-6. PubMed ID: 15939091
[TBL] [Abstract][Full Text] [Related]
40. Deciphering Rett syndrome with mouse genetics, epigenomics, and human neurons.
Tao J; Wu H; Sun YE
Int Rev Neurobiol; 2009; 89():147-60. PubMed ID: 19900619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
